A ceiling “maximum fair price” established by the Inflation Reduction Act will end up being an important driver of ...
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...
Medicare will negotiate prices for Part B injectable drugs for the first time, aiming to lower costs for millions of patients.
CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...
In the first year of the second Trump administration, we have seen the Food and Drug Administration (FDA) take an ...
Pharmaceutical innovation saves lives. But not every "new" drug is truly new. Such practices raise concerns about drug access and affordability, especially when companies use minor tweaks to block ...
Trump administration officials pledged Monday that major reforms for biosimilar drug approvals will expand access and lower prices for some of the most expensive drugs on the market. Food and Drug ...
Beth Woods is a health economist at the Centre for Health Economics, University of York, UK. Each year, more than nine million people in the United States do not take their medicines as prescribed ...
Lucy Xiaolu Wang does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results